

#2  
11/30/02

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

JC978 U.S. PTO  
09/995731  
11/29/01

In re application of

Alangudi SANKARANARAYANAN

Appl. No. CIP of 09/939,702 and 09/590,143

Group Art Unit: Unassigned

Confirmation No.: Unassigned

Examiner: Unassigned

Filed: November 29, 2001

For: COMPOSITION AND METHOD FOR USE OF PYRIDINIUM DERIVATIVES IN  
COSMETIC AND THERAPEUTIC APPLICATIONS

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office (International Search Report for PCT/IB99/01683 dated July 10, 2000).


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a

**INFORMATION DISCLOSURE STATEMENT**  
**U.S. Appln. No. -- CIP of 09/939,702 and 09/590,143**

request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



---

Abraham J. Rosner  
Registration No. 33,276

SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: November 29, 2001

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No. Q66697

Serial No.  
C100F09/939,702  
and 09/590,143

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Applicant : ALANGUDI SANKARANARAYANAN**

(Use several sheets if necessary)

Filing Date *November 29, 2001*

Group Unassigned

## U.S. PATENT DOCUMENTS

[illegible]

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No. *Q66697*

Serial No.

*CIP of 09/939,702  
and 09/590,143***INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**Applicant **ALANGUDI SANKARANARAYANAN**

(Use several sheets if necessary)

Filing Date *November 29, 2001*Group *Unassigned***FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	<b>822351A</b>	<b>10.21.1959</b>	<b>United Kingdom</b>	<b>C07d</b>			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	1.	Kenichi Shikata et al, Journal of Diabetes and its complications 1995:9: 269-271
	2.	Sara Vasan et al, Nature, vol 382, July 18, 1996, 275-278
	3.	M.Brownlee et al Science June 1986, 232: 1629-32
	4.	A Ceriello, Diab. Nutr. Metab.12: 42-46,1999
	5.	Horiuchi S et al, The Journal of Biological Chemistry 1991,266:7329-7332
	6.	Wolffenbuttel, B.H.R et al, Proc.Natl. Acad.Sci, USA, April 1998: 4630-4634
	7.	Mohammed Asif et al, PNAS March 14, 2000, vol 97, No.6, 2809-2813
✓	8.	Raj D S et al, Am J Kidney Dis Mar. 2000 35(3): 365-80
	9.	J.Shashi et al, Indian drugs 1995, 32(7) Pages 317-319 (XP 000909803)
✓	10.	Tiwari, S.S. et al, J. Indian Chem Soc, 1975, 52(2), 166-7 (XP 000909760)
✓	11.	Mocanu, G. et al, S.T.P. Pharma Sciences 1994, 4(4) 287-291 (XP 000909810)
✓	12.	Sarel, Shalom et al, J.Med. Chem. 1999, 42(2) 242-248 (XP 000910109)

Form PTO-1449  
(Rev. 2-32)U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No. *Q66697*

Serial No.

*CIP F09/939,702*  
*and 09/590,143*INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant **ALANGUDI SANKARANARAYANAN**

(Use several sheets if necessary)

Filing Date *November 29, 2001*Group *Unassigned*

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Contd...

		13.	Demchenko, A.M. et al, Chemistry of Heterocyclic compounds 1997, 33(10), 1191-1195 (XP 000909851)
		14.	Onodera, Akira et al, Chemical Abstracts, Vol 120, No 8, February 21, 1994, abstract no.90688 (XP 002139440)
	✓	15.	Pandey V.K. et al, Indian Drugs, 1983, 20(12), 492-4 (XP 000909902)
	✓	16.	Maksimovic, Matez et al, Chemical Abstracts, vol 96 No.13, March 29, 1982 abstract No. 99045 (XP 002139441)
	✓	17.	Binenfeld, Zlatko et al, Acta Pharm. Jugosl 1981, 31(1), 5-15 (XP 000909901)
	✓	18.	Ergenc, Nedime Chemical Abstracts Vol. 65, No. 6, September 12, 1966, abstract No.8891f (XP 002139442)
	✓	19.	Kao, Yee-Shang et al, Chemical Abstracts Vol 52, No.3, 1958 abstract No. 12860f (XP 002139443)
		20.	PCT Search report of Corresponding PCT application No.PCT/IB99/01683 <i>dated October July 10, 2000</i>

Examiner

Date Considered

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**